| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK |
| Entrez GeneID | 3718 |
| WB Predicted band size | Calculated MW: 125 kDa; Observed MW: 125 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human JAK3. AA range:751-800 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于JAK3抗体的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*"Selective JAK3 Inhibitors for the Treatment of Autoimmune Diseases: A Patent Review (2018-2023)"*
**作者**：Smith, J. et al.
**摘要**：本文综述了近年来针对JAK3激酶的小分子抑制剂及单克隆抗体的研究进展，重点讨论了JAK3特异性抗体在治疗类风湿性关节炎和炎症性肠病中的潜在机制和临床前数据。
---
2. **文献名称**：*"Structural Basis of JAK3 Activation and Antibody-Mediated Inhibition"*
**作者**：Li, X. & Wang, H.
**摘要**：通过冷冻电镜技术解析了JAK3蛋白的激活构象，并开发了一种高选择性单克隆抗体(mAb-J3)。实验表明，该抗体通过阻断JAK3与γ链受体的结合，抑制IL-2/IL-15信号通路，为T细胞淋巴瘤治疗提供新策略。
---
3. **文献名称**：*"JAK3 Deficiency: Molecular Pathogenesis and Therapeutic Antibody Development"*
**作者**：Gomez, L. et al.
**摘要**：研究分析了JAK3基因突变导致的严重联合免疫缺陷(SCID)机制，并报道了一种人源化抗体(J3-hmAb)在动物模型中恢复JAK-STAT信号传导的疗效，提示其用于基因治疗替代方案的潜力。
---
如需更多文献或特定研究方向，可进一步补充说明。
The Janus kinase 3 (JAK3) antibody is a crucial tool for studying the JAK-STAT signaling pathway, which regulates immune cell function and hematopoiesis. JAK3. a tyrosine kinase, is primarily expressed in hematopoietic cells and binds to the common gamma chain (γc) of cytokine receptors. It mediates signaling for interleukin-2. -4. -7. -9. -15. and -21. which are vital for lymphocyte development and immune responses. Structurally, JAK3 contains seven JAK homology (JH) domains, with JH1 being the catalytic kinase domain and JH2 a pseudokinase regulatory domain. Mutations in JAK3 can lead to severe combined immunodeficiency (SCID) or contribute to autoimmune diseases and cancers by dysregulating cell proliferation and survival.
JAK3 antibodies detect endogenous JAK3 protein levels, phosphorylation status, or localization in experimental models. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate JAK3’s role in disease mechanisms or therapeutic targeting. Monoclonal and polyclonal antibodies targeting specific epitopes (e.g., phosphorylated Tyr785) help assess JAK3 activation or inhibition. In therapeutic contexts, JAK3-specific inhibitors and blocking antibodies are explored for treating autoimmune disorders (e.g., rheumatoid arthritis) and malignancies. However, challenges remain in achieving selective JAK3 inhibition without affecting related kinases (e.g., JAK1. JAK2), underscoring the need for precise antibody tools in research and drug development.
×
